EGFR and non-small cell lung carcinoma: Additionally, clinical trials are being initiated to explore the neoadjuvant role of furmonertinib in combination with bevacizumab (NCT 05503667) or cisplatin/pemetrexed (FORESEE, NCT05430802) for resectable and potentially resectable stage III-IVA or stage IIIA-IIIB EGFR mutant NSCLC in China.